Entecavir or tenofovir

nucleo(s/t)ide analogs, well tolerated, low resistance; at 5 y, HBeAg seroconversion is 30–40% & loss of HBsAg is 5–10% (Lancet Gastro Hep 2016;1:185). Tenofovir preferred if h/o lamivudine resistance; no known tenofovir resistance to date.